The ERA Registry Annual Report 2020: a summary

Megan E. Astley; Rianne Boenink; Samar Abd ElHafeez; Sara Trujillo-Alemán; Federico Arribas; Anders Åsberg; Pazit Beckerman; Samira Bell; María Encarnación Bouzas-Caamaño; Jordi Comas Farnés; Ana Amélia Galvão; Nikola Gjorgjievski; Vjollca Godanci Kelmendi; Rebecca Guidotti; Jaakko Helve; Alma Idrizi; Ólafur S Indriðason; Kyriakos Ioannou; Julia Kerschbaum; Kirill Komissarov; Pablo Castro de la Nuez; Mathilde Lassalle; Maurizio Nordio; Olga Lucía Rodríguez Arévalo; Carmen Santiuste; Nurhan Seyahi; María Fernanda Slon Roblero; Retha Steenkamp; Marc A. G. J. Ten Dam; Elena V Zakharova; Edita Ziginskiene; Marjolein Bonthuis; Vianda S. Stel; Alberto Ortiz; Kitty J. Jager; Anneke Kramer

doi:10.1093/ckj/sfad087

The ERA Registry Annual Report 2020: a summary

Megan E. Astley (Lead / Corresponding author), Rianne Boenink, Samar Abd ElHafeez, Sara Trujillo-Alemán, Federico Arribas, Anders Åsberg, Pazit Beckerman, Samira Bell, María Encarnación Bouzas-Caamaño, Jordi Comas Farnés, Ana Amélia Galvão, Nikola Gjorgjievski, Vjollca Godanci Kelmendi, Rebecca Guidotti, Jaakko Helve, Alma Idrizi, Ólafur S Indriðason, Kyriakos Ioannou, Julia Kerschbaum, Kirill KomissarovPablo Castro de la Nuez, Mathilde Lassalle, Maurizio Nordio, Olga Lucía Rodríguez Arévalo, Carmen Santiuste, Nurhan Seyahi, María Fernanda Slon Roblero, Retha Steenkamp, Marc A. G. J. Ten Dam, Elena V Zakharova, Edita Ziginskiene, Marjolein Bonthuis, Vianda S. Stel, Alberto Ortiz, Kitty J. Jager, Anneke Kramer

Population Health and Genomics

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

47 Downloads (Pure)

Abstract

Background: The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with ESKD. This paper is a summary of the ERA Registry Annual Report 2020, also including comparisons among primary renal disease (PRD) groups.

Methods: Data were collected from 52 national and regional registries from 34 European countries and countries bordering the Mediterranean Sea: 35 registries from 18 countries providing individual level data and 17 registries from 17 countries providing aggregated data. Using this data, KRT incidence and prevalence, kidney transplantation rates, expected remaining lifetimes and survival probabilities were calculated.

Results: A general population of 654.9 million people was covered by the ERA Registry in 2020. The overall incidence of KRT was 128 per million population (p.m.p.). In incident KRT patients, 54% were older than 65 years, 63% were men and the most common PRD was diabetes mellitus (21%). Regarding initial treatment modality in incident patients, 85% received haemodialysis (HD), 11% received peritoneal dialysis (PD) and 4% received a pre-emptive kidney transplant. On 31 December 2020, the prevalence of KRT was 931 p.m.p. In prevalent patients, 45% were older than 65 years, 60% were men and glomerulonephritis was the most common PRD (18%). Of these patients, 58% were on HD, 5% on PD and 37% were living with a kidney transplant. The overall kidney transplantation rate in 2020 was 28 p.m.p., with a majority of kidney grafts from deceased donors (71%). The unadjusted 5-year survival, based on incident dialysis patient from 2011-15, was 41.8%. For patients having received a deceased donor transplant, the unadjusted 5-year survival probability was 86.2% and for patients having received a living donor transplant it was 94.4%. When comparing data by PRD group, differences were found regarding the distribution of age groups, sex and treatment modality received.

Original language	English
Pages (from-to)	1330-1354
Number of pages	25
Journal	Clinical Kidney Journal
Volume	16
Issue number	8
Early online date	21 Apr 2023
DOIs	https://doi.org/10.1093/ckj/sfad087
Publication status	Published - Aug 2023

Keywords

dialysis
epidemiology
ESKD
kidney transplantation
patient survival

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ckj/sfad087Licence: CC BY-NC

Final Published VersionFinal published version, 4.74 MBLicence: CC BY-NC

Cite this

Astley, M. E., Boenink, R., Abd ElHafeez, S., Trujillo-Alemán, S., Arribas, F., Åsberg, A., Beckerman, P., Bell, S., Bouzas-Caamaño, M. E., Farnés, J. C., Galvão, A. A., Gjorgjievski, N., Kelmendi, V. G., Guidotti, R., Helve, J., Idrizi, A., Indriðason, Ó. S., Ioannou, K., Kerschbaum, J., ... Kramer, A. (2023). The ERA Registry Annual Report 2020: a summary. Clinical Kidney Journal, 16(8), 1330-1354. https://doi.org/10.1093/ckj/sfad087

@article{3f6c3068e07c48b59bea918e79951308,

title = "The ERA Registry Annual Report 2020: a summary",

abstract = "Background: The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with ESKD. This paper is a summary of the ERA Registry Annual Report 2020, also including comparisons among primary renal disease (PRD) groups.Methods: Data were collected from 52 national and regional registries from 34 European countries and countries bordering the Mediterranean Sea: 35 registries from 18 countries providing individual level data and 17 registries from 17 countries providing aggregated data. Using this data, KRT incidence and prevalence, kidney transplantation rates, expected remaining lifetimes and survival probabilities were calculated.Results: A general population of 654.9 million people was covered by the ERA Registry in 2020. The overall incidence of KRT was 128 per million population (p.m.p.). In incident KRT patients, 54% were older than 65 years, 63% were men and the most common PRD was diabetes mellitus (21%). Regarding initial treatment modality in incident patients, 85% received haemodialysis (HD), 11% received peritoneal dialysis (PD) and 4% received a pre-emptive kidney transplant. On 31 December 2020, the prevalence of KRT was 931 p.m.p. In prevalent patients, 45% were older than 65 years, 60% were men and glomerulonephritis was the most common PRD (18%). Of these patients, 58% were on HD, 5% on PD and 37% were living with a kidney transplant. The overall kidney transplantation rate in 2020 was 28 p.m.p., with a majority of kidney grafts from deceased donors (71%). The unadjusted 5-year survival, based on incident dialysis patient from 2011-15, was 41.8%. For patients having received a deceased donor transplant, the unadjusted 5-year survival probability was 86.2% and for patients having received a living donor transplant it was 94.4%. When comparing data by PRD group, differences were found regarding the distribution of age groups, sex and treatment modality received.",

keywords = "dialysis, epidemiology, ESKD, kidney transplantation, patient survival",

author = "Astley, {Megan E.} and Rianne Boenink and {Abd ElHafeez}, Samar and Sara Trujillo-Alem{\'a}n and Federico Arribas and Anders {\AA}sberg and Pazit Beckerman and Samira Bell and Bouzas-Caama{\~n}o, {Mar{\'i}a Encarnaci{\'o}n} and Farn{\'e}s, {Jordi Comas} and Galv{\~a}o, {Ana Am{\'e}lia} and Nikola Gjorgjievski and Kelmendi, {Vjollca Godanci} and Rebecca Guidotti and Jaakko Helve and Alma Idrizi and Indri{\dh}ason, {{\'O}lafur S} and Kyriakos Ioannou and Julia Kerschbaum and Kirill Komissarov and {Castro de la Nuez}, Pablo and Mathilde Lassalle and Maurizio Nordio and Ar{\'e}valo, {Olga Luc{\'i}a Rodr{\'i}guez} and Carmen Santiuste and Nurhan Seyahi and Roblero, {Mar{\'i}a Fernanda Slon} and Retha Steenkamp and {Ten Dam}, {Marc A. G. J.} and Zakharova, {Elena V} and Edita Ziginskiene and Marjolein Bonthuis and Stel, {Vianda S.} and Alberto Ortiz and Jager, {Kitty J.} and Anneke Kramer",

note = "Funding Information: The ERA Registry is funded by the European Renal Association (ERA). This article was written by M.E.A. et al. on behalf of the ERA Registry, which is an official body of the ERA. In addition, A.O. reports grants from Sanofi and personal fees from Astellas, AstraZeneca, Amicus, Bayes, Fresenius Medical care and Idorsia, outside the submitted work. K.J.J. reports grants from ERA, during the conduct of the study, and lecture and presentation fees from Fresenius. V.S.S. reports receiving grants from the ERA. A.{\AA}. reports receiving study grants from AstraZeneca and CEPI, and speaker fees from Orifarm and Sandoz. O.S.I. reports grants from the Landspitali University Hospital Science Fund. M.F.S.R. reports receiving consulting fees and payment from Baxter and Fresenius. J.C.F. reports receiving payment for presentation from the TPM-DTI Foundation. P.A. reports receiving consulting fees from Astellas and CSL-Vifor. P.C.N. reports receiving support from Sistema Sanitario P{\'u}blico de Andaluc{\'i}a. Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.",

year = "2023",

month = aug,

doi = "10.1093/ckj/sfad087",

language = "English",

volume = "16",

pages = "1330--1354",

journal = "Clinical Kidney Journal",

issn = "2048-8505",

publisher = "Oxford University Press",

number = "8",

}

Astley, ME, Boenink, R, Abd ElHafeez, S, Trujillo-Alemán, S, Arribas, F, Åsberg, A, Beckerman, P, Bell, S, Bouzas-Caamaño, ME, Farnés, JC, Galvão, AA, Gjorgjievski, N, Kelmendi, VG, Guidotti, R, Helve, J, Idrizi, A, Indriðason, ÓS, Ioannou, K, Kerschbaum, J, Komissarov, K, Castro de la Nuez, P, Lassalle, M, Nordio, M, Arévalo, OLR, Santiuste, C, Seyahi, N, Roblero, MFS, Steenkamp, R, Ten Dam, MAGJ, Zakharova, EV, Ziginskiene, E, Bonthuis, M, Stel, VS, Ortiz, A, Jager, KJ & Kramer, A 2023, 'The ERA Registry Annual Report 2020: a summary', Clinical Kidney Journal, vol. 16, no. 8, pp. 1330-1354. https://doi.org/10.1093/ckj/sfad087

TY - JOUR

T1 - The ERA Registry Annual Report 2020

T2 - a summary

AU - Astley, Megan E.

AU - Boenink, Rianne

AU - Abd ElHafeez, Samar

AU - Trujillo-Alemán, Sara

AU - Arribas, Federico

AU - Åsberg, Anders

AU - Beckerman, Pazit

AU - Bell, Samira

AU - Bouzas-Caamaño, María Encarnación

AU - Farnés, Jordi Comas

AU - Galvão, Ana Amélia

AU - Gjorgjievski, Nikola

AU - Kelmendi, Vjollca Godanci

AU - Guidotti, Rebecca

AU - Helve, Jaakko

AU - Idrizi, Alma

AU - Indriðason, Ólafur S

AU - Ioannou, Kyriakos

AU - Kerschbaum, Julia

AU - Komissarov, Kirill

AU - Castro de la Nuez, Pablo

AU - Lassalle, Mathilde

AU - Nordio, Maurizio

AU - Arévalo, Olga Lucía Rodríguez

AU - Santiuste, Carmen

AU - Seyahi, Nurhan

AU - Roblero, María Fernanda Slon

AU - Steenkamp, Retha

AU - Ten Dam, Marc A. G. J.

AU - Zakharova, Elena V

AU - Ziginskiene, Edita

AU - Bonthuis, Marjolein

AU - Stel, Vianda S.

AU - Ortiz, Alberto

AU - Jager, Kitty J.

AU - Kramer, Anneke

N1 - Funding Information: The ERA Registry is funded by the European Renal Association (ERA). This article was written by M.E.A. et al. on behalf of the ERA Registry, which is an official body of the ERA. In addition, A.O. reports grants from Sanofi and personal fees from Astellas, AstraZeneca, Amicus, Bayes, Fresenius Medical care and Idorsia, outside the submitted work. K.J.J. reports grants from ERA, during the conduct of the study, and lecture and presentation fees from Fresenius. V.S.S. reports receiving grants from the ERA. A.Å. reports receiving study grants from AstraZeneca and CEPI, and speaker fees from Orifarm and Sandoz. O.S.I. reports grants from the Landspitali University Hospital Science Fund. M.F.S.R. reports receiving consulting fees and payment from Baxter and Fresenius. J.C.F. reports receiving payment for presentation from the TPM-DTI Foundation. P.A. reports receiving consulting fees from Astellas and CSL-Vifor. P.C.N. reports receiving support from Sistema Sanitario Público de Andalucía. Copyright: © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.

PY - 2023/8

Y1 - 2023/8

N2 - Background: The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with ESKD. This paper is a summary of the ERA Registry Annual Report 2020, also including comparisons among primary renal disease (PRD) groups.Methods: Data were collected from 52 national and regional registries from 34 European countries and countries bordering the Mediterranean Sea: 35 registries from 18 countries providing individual level data and 17 registries from 17 countries providing aggregated data. Using this data, KRT incidence and prevalence, kidney transplantation rates, expected remaining lifetimes and survival probabilities were calculated.Results: A general population of 654.9 million people was covered by the ERA Registry in 2020. The overall incidence of KRT was 128 per million population (p.m.p.). In incident KRT patients, 54% were older than 65 years, 63% were men and the most common PRD was diabetes mellitus (21%). Regarding initial treatment modality in incident patients, 85% received haemodialysis (HD), 11% received peritoneal dialysis (PD) and 4% received a pre-emptive kidney transplant. On 31 December 2020, the prevalence of KRT was 931 p.m.p. In prevalent patients, 45% were older than 65 years, 60% were men and glomerulonephritis was the most common PRD (18%). Of these patients, 58% were on HD, 5% on PD and 37% were living with a kidney transplant. The overall kidney transplantation rate in 2020 was 28 p.m.p., with a majority of kidney grafts from deceased donors (71%). The unadjusted 5-year survival, based on incident dialysis patient from 2011-15, was 41.8%. For patients having received a deceased donor transplant, the unadjusted 5-year survival probability was 86.2% and for patients having received a living donor transplant it was 94.4%. When comparing data by PRD group, differences were found regarding the distribution of age groups, sex and treatment modality received.

AB - Background: The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with ESKD. This paper is a summary of the ERA Registry Annual Report 2020, also including comparisons among primary renal disease (PRD) groups.Methods: Data were collected from 52 national and regional registries from 34 European countries and countries bordering the Mediterranean Sea: 35 registries from 18 countries providing individual level data and 17 registries from 17 countries providing aggregated data. Using this data, KRT incidence and prevalence, kidney transplantation rates, expected remaining lifetimes and survival probabilities were calculated.Results: A general population of 654.9 million people was covered by the ERA Registry in 2020. The overall incidence of KRT was 128 per million population (p.m.p.). In incident KRT patients, 54% were older than 65 years, 63% were men and the most common PRD was diabetes mellitus (21%). Regarding initial treatment modality in incident patients, 85% received haemodialysis (HD), 11% received peritoneal dialysis (PD) and 4% received a pre-emptive kidney transplant. On 31 December 2020, the prevalence of KRT was 931 p.m.p. In prevalent patients, 45% were older than 65 years, 60% were men and glomerulonephritis was the most common PRD (18%). Of these patients, 58% were on HD, 5% on PD and 37% were living with a kidney transplant. The overall kidney transplantation rate in 2020 was 28 p.m.p., with a majority of kidney grafts from deceased donors (71%). The unadjusted 5-year survival, based on incident dialysis patient from 2011-15, was 41.8%. For patients having received a deceased donor transplant, the unadjusted 5-year survival probability was 86.2% and for patients having received a living donor transplant it was 94.4%. When comparing data by PRD group, differences were found regarding the distribution of age groups, sex and treatment modality received.

KW - dialysis

KW - epidemiology

KW - ESKD

KW - kidney transplantation

KW - patient survival

U2 - 10.1093/ckj/sfad087

DO - 10.1093/ckj/sfad087

M3 - Article

C2 - 37529647

SN - 2048-8505

VL - 16

SP - 1330

EP - 1354

JO - Clinical Kidney Journal

JF - Clinical Kidney Journal

IS - 8

ER -

The ERA Registry Annual Report 2020: a summary

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this